Document is current
Any future updates will be listed below
-
Authors
Noorduyn, Stephen G. https://orcid.org/0000-0002-5936-5579
Brown, Nicola
Crawford, Jodie
Demetriou, Lydia https://orcid.org/0009-0004-4665-279X
Ismaila, Afisi S. https://orcid.org/0000-0002-2876-8308
Mbuagbaw, Lawrence https://orcid.org/0000-0001-5855-5461
Parpia, Sameer https://orcid.org/0000-0002-9407-5622
Sadeghirad, Behnam https://orcid.org/0000-0001-9422-5232
Slade, David
Moore, Alison C.
-
Funding
Funding for this research was provided by:
GSK (219912)
- License Information
-
More Information
Article History
Received: 10 November 2025
Accepted: 15 January 2026
First Online: 12 February 2026
Declarations
:
: Lawrence Mbuagbaw, Sameer Parpia and Behnam Sadeghirad have nothing to disclose. Stephen G. Noorduyn, Nicola Brown, Jodie Crawford, Lydia Demetriou, Afisi S. Ismaila, David Slade and Alison C. Moore are employees of and hold financial equities in GSK. Stephen G. Noorduyn is also a PhD candidate at McMaster University, Hamilton, ON, Canada. Afisi S. Ismaila is also an unpaid part-time member of McMaster University.
: This protocol was approved by the ethics committee (Table ). All patients will be asked to provide written informed consent. This trial will be conducted in accordance with applicable local regulations and the principles stated in the Declaration of Helsinki of 1964 and its later amendments, the Council for International Organisations of Medical Sciences International Ethical Guidelines for Health-related Research Involving Humans, and the International Conference on Harmonisation Tripartite Guideline for Good Clinical Practice.
